Figures & data
Tabel I. Dose escalation and reduction scheme (mg/m2).
Table II. Consort diagram.
Table III. Patient characteristics.
Table IV. Relative dose intensity.
Table V. Treatment feasibility: number of treatments, number of treatment delays and omitted treatments.
Figure 1. Distribution of nadir leukocytes after courses 1–7. Cumulative percentage of patients in the three study arms on the x-axis with nadir values below value as indicated on the y-axis.
![Figure 1. Distribution of nadir leukocytes after courses 1–7. Cumulative percentage of patients in the three study arms on the x-axis with nadir values below value as indicated on the y-axis.](/cms/asset/c77e7fe1-c56e-4832-bb6b-06705fb50c3a/ionc_a_554435_f0001_b.gif)
Table VI. Max grade of leukopenia during courses 2–7.
Table VII. Non-haematological side-effects during courses 2–7.